ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31

ADC Therapeutics SA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.44+0.04 (+2.86%)

Close on Oct 19, 2026

Market cap: $223.22M
P/E (TTM): –
Dividend yield: –

ADC Therapeutics SA balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Cash & Equivalents	261	251	279	326	467	439	116	139	263
Cash & Short-Term Investments	261	251	279	326	467	439	116	139	263
Receivables	–	–	–	73	30	0	–	–	–
Inventory	4.18	2.25	16	12	11	0	–	–	–
Prepaid Expenses & Other	5.61	8.37	10	23	–	–	–	–	–
Other Current Assets	6.08	9.45	5.99	28	17	11	7.06	–	–
Total Current Assets	306	291	336	435	525	450	123	–	–
Property, Plant & Equipment	0	5.08	5.62	3.36	4.07	1.63	1.38	–	–
Gross Property, Plant & Equipment	1.38	10	9.90	6.76	–	–	–	–	–
Accumulated Depreciation	-1.38	-5.32	-4.28	-3.41	–	–	–	–	–
Equity Method Investments	–	0	1.65	7.61	–	–	–	–	–
Operating Lease Right-of-Use Assets	1.30	8.35	11	6.91	7.16	3.13	4.90	–	–
Intangible Assets	–	–	–	14	14	10	8.43	–	–
Deferred Tax Assets	–	–	0	37	–	–	–	–	–
Other Long-Term Assets	1.22	1.16	0.71	0.90	0.69	0.40	0.37	–	–
Total Assets	323	322	355	491	618	514	138	–	–
Accounts Payable	9.18	18	16	12	12	5.28	3.33	–	–
Accrued Expenses	58	62	52	68	–	–	–	–	–
Short-Term Debt	–	–	–	12	–	–	–	–	–
Current Portion of Long-Term Debt	3.00	0	–	–	–	–	–	–	–
Current Debt	3.00	0	–	12	6.58	3.63	0	–	–
Current Portion of Leases	0.54	1.37	1.47	1.10	1.03	1.00	0.92	0.92	–
Current Income Taxes Payable	–	–	–	0	3.75	0.15	0.05	–	–
Total Current Liabilities	70	80	68	82	74	40	20	–	–
Long-Term Debt	–	–	–	–	87	35	0	–	–
Long-Term Leases	1.03	8.00	10	6.56	6.99	2.47	4.50	4.50	–
Operating Lease Liabilities	1.57	9.37	12	7.66	8.02	3.47	5.03	5.42	–
Deferred Tax Liabilities	0.79	1.91	1.33	3.99	–	–	–	–	–
Other Long-Term Liabilities	2.81	2.43	8.88	0.84	0	0.22	0	–	–
Total Liabilities	509	525	503	411	452	178	27	–	–
Total Debt	3.00	0	–	12	94	38	0	–	–
Common Stock	11	8.43	7.31	7.31	6.45	6.31	4.36	–	–
Additional Paid-In Capital	1,440	1,284	1,181	1,166	982	981	550	–	–
Retained Earnings	-1,636	-1,493	-1,335	-1,095	-925	-695	-449	–	–
Treasury Stock	-0.21	-0.22	-0.54	-0.68	-0.13	0.00	-0.10	–	–
Comprehensive Income & Other	-0.52	-1.42	-0.09	1.82	–	–	–	–	–
Shareholders' Equity	-186	-203	-148	79	154	–	–	–	–
Total Equity	-186	-203	-148	79	154	336	111	126	249
Total Liabilities & Equity	323	322	355	491	618	514	138	–	–
Shares Outstanding(shares)	126	99	82	81	–	77	52	48	47

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 94.9%
Operating margin: -125.1%
Net margin: -121.8%
Return on equity, FY2025: 73.4%

Financial strength

Current ratio: 3.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 253.8%

Valuation

P/E ratio: –
Price to sales: 2.80
Price to book: –
Dividend yield: –